Spark Therapeutics Inc. (NASDAQ:ONCE)’s share price traded up 4.3% on Wednesday . The company traded as high as $55.14 and last traded at $54.69, with a volume of 161,309 shares traded. The stock had previously closed at $52.45.

A number of brokerages have recently issued reports on ONCE. Royal Bank Of Canada began coverage on shares of Spark Therapeutics in a report on Tuesday, July 12th. They issued an “outperform” rating and a $70.00 price target on the stock. Jefferies Group reissued a “hold” rating on shares of Spark Therapeutics in a report on Sunday, June 12th. Cowen and Company reissued a “buy” rating and issued a $75.00 price target on shares of Spark Therapeutics in a report on Thursday, May 19th. Cantor Fitzgerald began coverage on shares of Spark Therapeutics in a report on Thursday, June 2nd. They issued a “buy” rating and a $100.00 price target on the stock. Finally, Zacks Investment Research raised shares of Spark Therapeutics from a “hold” rating to a “buy” rating and set a $41.00 price target on the stock in a report on Friday, April 29th. Three research analysts have rated the stock with a sell rating, four have given a hold rating and seven have given a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $58.70.

The firm’s 50 day moving average price is $51.34 and its 200 day moving average price is $38.92. The company’s market cap is $1.49 billion.

Spark Therapeutics (NASDAQ:ONCE) last issued its earnings results on Wednesday, May 4th. The company reported ($0.95) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.84) by $0.11. The business earned $1.29 million during the quarter, compared to analyst estimates of $1.48 million. The firm’s revenue for the quarter was down 43.2% on a year-over-year basis. On average, analysts anticipate that Spark Therapeutics Inc. will post ($3.84) EPS for the current fiscal year.

In other Spark Therapeutics news, insider Barge Joseph La sold 10,000 shares of the business’s stock in a transaction dated Friday, May 20th. The stock was sold at an average price of $47.65, for a total value of $476,500.00. Following the completion of the transaction, the insider now owns 12,825 shares of the company’s stock, valued at approximately $611,111.25. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Hospital Of Philade Children’s sold 1,000,000 shares of the business’s stock in a transaction dated Monday, June 20th. The stock was sold at an average price of $42.30, for a total value of $42,300,000.00. Following the completion of the transaction, the insider now directly owns 6,768,707 shares of the company’s stock, valued at approximately $286,316,306.10. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Spark Therapeutics stock. TD Asset Management Inc. boosted its position in shares of Spark Therapeutics Inc. (NASDAQ:ONCE) by 72.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 58,187 shares of the company’s stock after buying an additional 24,400 shares during the period. TD Asset Management Inc. owned about 0.24% of Spark Therapeutics worth $2,636,000 at the end of the most recent quarter.

Spark Therapeutics, Inc (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.